Literature DB >> 9646010

Therapeutic drug monitoring of clozapine treatment. Therapeutic threshold value for serum clozapine concentrations.

O V Olesen1.   

Abstract

It has been suggested that the minimum effective serum clozapine concentration for an acceptable clinical response (threshold value) is about 400 micrograms/L. This article argues against the use of therapeutic drug monitoring (TDM) as a tool to obtain clozapine concentrations of > or = 400 micrograms/L in the individual patient from the start of clozapine treatment. The following arguments are presented: (i) because of a great interindividual variability of the clozapine concentration to dose ratio (C/D) it can be calculated that extremely high daily doses (900 to 1800 mg/day) would be necessary in 15% of patients to obtain a clozapine concentration of 400 micrograms/L; (ii) doses of 200 to 300 mg/day are commonly used in Central Europe. although about 80% of the patients can be expected to have clozapine concentration < 400 micrograms/L; (iii) in a double-blind study, no difference in clinical response was found between patients treated with clozapine in the concentration range of 200 to 300 micrograms/L, and a group with higher clozapine concentrations; (iv) positron emission topography (PET) studies indicate that maximum receptor occupancy is obtained at clozapine concentrations of about 200 micrograms/L and no further receptor occupancy is obtained by increasing clozapine concentrations to > or = 400 micrograms/L; (v) the frequency of both severe clozapine-induced adverse effects (seizure and confusion) and more common adverse effects increases with increasing doses/clozapine concentrations. It is concluded that the antipsychotic effects and adverse effects of clozapine occur over a very broad range of serum concentrations. In most countries the majority of patients are treated with clozapine concentrations well below the 400 micrograms/L suggested as threshold concentration for optimum response. Therefore clinical judgement should always be primarily used for dose adjustments. TDM is useful to follow compliance and to adjust for extreme serum concentrations and revealing drug interactions.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9646010     DOI: 10.2165/00003088-199834060-00005

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  18 in total

1.  Clozapine concentrations and clinical response in schizophrenic patients.

Authors:  J A Owen; N J Delva; J S Lawson
Journal:  Am J Psychiatry       Date:  1992-08       Impact factor: 18.112

2.  Plasma clozapine levels and clinical response for treatment-refractory schizophrenic patients.

Authors:  M H Kronig; R A Munne; S Szymanski; A Z Safferman; S Pollack; T Cooper; J M Kane; J A Lieberman
Journal:  Am J Psychiatry       Date:  1995-02       Impact factor: 18.112

Review 3.  Will routine therapeutic drug monitoring have a place in clozapine therapy?

Authors:  D J Freeman; L K Oyewumi
Journal:  Clin Pharmacokinet       Date:  1997-02       Impact factor: 6.447

4.  [Serious drug interaction between clozapine-Leponex and fluvoxamine-Fevarin].

Authors:  O V Olesen; G Starup; K Linnet
Journal:  Ugeskr Laeger       Date:  1996-11-25

Review 5.  Clozapine dose in the United States and Europe: implications for therapeutic and adverse effects.

Authors:  W W Fleischhacker; M Hummer; M Kurz; I Kurzthaler; J A Lieberman; S Pollack; A Z Safferman; J M Kane
Journal:  J Clin Psychiatry       Date:  1994-09       Impact factor: 4.384

6.  Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: evidence from a therapeutic drug monitoring service.

Authors:  M Jerling; L Lindström; U Bondesson; L Bertilsson
Journal:  Ther Drug Monit       Date:  1994-08       Impact factor: 3.681

7.  D1, D2, and 5-HT2 receptor occupancy in relation to clozapine serum concentration: a PET study of schizophrenic patients.

Authors:  A L Nordström; L Farde; S Nyberg; P Karlsson; C Halldin; G Sedvall
Journal:  Am J Psychiatry       Date:  1995-10       Impact factor: 18.112

8.  Relationship between clinical efficacy and clozapine concentrations in plasma in schizophrenia: effect of smoking.

Authors:  M Hasegawa; R Gutierrez-Esteinou; L Way; H Y Meltzer
Journal:  J Clin Psychopharmacol       Date:  1993-12       Impact factor: 3.153

9.  A case report of cimetidine-induced clozapine toxicity.

Authors:  S Szymanski; J A Lieberman; D Picou; S Masiar; T Cooper
Journal:  J Clin Psychiatry       Date:  1991-01       Impact factor: 4.384

10.  Can low-dose clozapine pharmacokinetics predict steady-state plasma concentration?

Authors:  L K Oyewumi; D J Freeman; D Vollick
Journal:  Ther Drug Monit       Date:  1995-04       Impact factor: 3.681

View more
  10 in total

Review 1.  Clinically significant pharmacokinetic interactions between dietary caffeine and medications.

Authors:  J A Carrillo; J Benitez
Journal:  Clin Pharmacokinet       Date:  2000-08       Impact factor: 6.447

2.  A Comparative Study of the Pharmacokinetics of Clozapine N-Oxide and Clozapine N-Oxide Hydrochloride Salt in Rhesus Macaques.

Authors:  Daicia C Allen; Timothy L Carlson; Yan Xiong; Jian Jin; Kathleen A Grant; Verginia C Cuzon Carlson
Journal:  J Pharmacol Exp Ther       Date:  2018-12-06       Impact factor: 4.030

Review 3.  Atypical neuroleptics in child and adolescent psychiatry.

Authors:  H Remschmidt; K Hennighausen; H W Clement; P Heiser; E Schulz
Journal:  Eur Child Adolesc Psychiatry       Date:  2000       Impact factor: 4.785

Review 4.  What is an adequate trial with clozapine?: therapeutic drug monitoring and time to response in treatment-refractory schizophrenia.

Authors:  Peter Schulte
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 5.  Clozapine and therapeutic drug monitoring: is there sufficient evidence for an upper threshold?

Authors:  Gary Remington; Ofer Agid; George Foussias; Larissa Ferguson; Krysta McDonald; Valerie Powell
Journal:  Psychopharmacology (Berl)       Date:  2012-11-22       Impact factor: 4.530

Review 6.  Management of schizophrenia in children and adolescents. The role of clozapine.

Authors:  H Remschmidt; C Fleischhaker; K Hennighausen; E Schulz
Journal:  Paediatr Drugs       Date:  2000 Jul-Aug       Impact factor: 3.930

7.  Multidimensional mapping method using an arrayed sensing system for cross-reactivity screening.

Authors:  Sheryl E Chocron; Bryce M Weisberger; Hadar Ben-Yoav; Thomas E Winkler; Eunkyoung Kim; Deanna L Kelly; Gregory F Payne; Reza Ghodssi
Journal:  PLoS One       Date:  2015-03-19       Impact factor: 3.240

8.  Role of Statistical Random-Effects Linear Models in Personalized Medicine.

Authors:  Francisco J Diaz; Hung-Wen Yeh; Jose de Leon
Journal:  Curr Pharmacogenomics Person Med       Date:  2012-03

Review 9.  A Rational Use of Clozapine Based on Adverse Drug Reactions, Pharmacokinetics, and Clinical Pharmacopsychology.

Authors:  Jose de Leon; Can-Jun Ruan; Georgios Schoretsanitis; Carlos De Las Cuevas
Journal:  Psychother Psychosom       Date:  2020-04-14       Impact factor: 17.659

10.  Combining Therapeutic Drug Monitoring and Pharmacokinetic Modelling Deconvolutes Physiological and Environmental Sources of Variability in Clozapine Exposure.

Authors:  Kenneth H Wills; Stephen J Behan; Michael J Nance; Jessica L Dawson; Thomas M Polasek; Ashley M Hopkins; Madelé van Dyk; Andrew Rowland
Journal:  Pharmaceutics       Date:  2021-12-27       Impact factor: 6.321

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.